ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Study finds CDK4/6 plus EGFR blockade kills pancreatic cancer cells without KRAS drugs

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
Medscape

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...
Medscape

Staying the Course After EGFR Progression: A Practical Guide to Treatment in NSCLC

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a ...
News Medical

Inhibiting palmitate-adding enzyme can make cancer cells sensitive to EGFR inhibitors

The mistaken activation of certain cell-surface receptors contributes to a variety of human cancers. Knowing more about the activation process has led researchers to be able to induce greater ...
Healio

Phase 3 results for pegcetacoplan show reduced proteinuria, stabilized eGFR vs. placebo

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Sobi and Apellis Pharmaceuticals Inc. announced positive ...